Competitive Intelligence Brief — NSCLC Pre-Launch, US Market

The Opportunity and the Risk

NSCLC is the largest IO market in oncology. It is also the most divided. A new entrant that does not understand the cohort structure will price and position for the wrong patients.

Four approved IO agents have divided the first-line patient pool into distinct biomarker cohorts — each with a different dominant agent, different clinical precedents, and different payer coverage criteria. Pembrolizumab controls the PD-L1 ≥50% monotherapy setting through five years of clinical and commercial precedent. Combination regimens have set a different standard below that threshold. These cohorts are not interchangeable, and a single commercial strategy will not address both.

US payer coverage criteria for IO agents in NSCLC were written around the early KEYNOTE and CheckMate trials. New entrants are evaluated against those precedents — not against their own trial designs. The evidence a payer will require at your approval is already visible in the coverage policies for existing agents. The window to shape that conversation is 12 to 18 months pre-approval, not at launch.

Below, we map that landscape and frame the decisions your commercial team needs to make before strategy is locked.

IO agents with US first-line NSCLC approval — each holding a distinct patient cohort

~60%

NSCLC patients IO-eligible after molecular exclusions and biomarker stratification

Distinct PD-L1 cohorts with different competitive dynamics, different KOL positions, different payer standards

2028

Pembrolizumab US patent expiry — first biosimilar IO entry window opening in the dominant cohort

What Your Team Needs Answered

Five commercial questions. Each section is built to answer one of them.

Structured by decision, not by topic. Every section produces a named output that feeds a specific call your team will have to make — on positioning, on access, on where to compete.

What is the addressable patient pool — by PD-L1 cohort and line of therapy?

DeliversPatient funnel from incidence to IO-eligible · PD-L1 cohort breakdown · five-year projection with testing-rate sensitivity

Which agents control which cohorts — and what clinical differentiation has actually moved share?

DeliversAgent map by cohort · pivotal trial comparison (OS · PFS · ORR) · estimated prescribing share

What evidence thresholds are US payers applying — and does your clinical profile clear them?

DeliversCoverage criteria by agent · prior authorisation requirements · gap analysis vs. your trial design

Where are the unmet needs current agents have not addressed — and is your mechanism aligned to them?

DeliversNon-responder and progression-after-IO cohort mapping · biomarker gap analysis · MOA alignment assessment

What are the realistic patient capture scenarios at Year 1, Year 3, and Year 5 — by cohort?

DeliversThree-scenario share model · ranked assumption drivers · revenue sensitivity table

Scoped to your asset, your proposed label, and your target cohort — not the market in aggregate.

Scope Your Work

Inside the Brief

Eight sections. Every section structured around a named commercial question.

What your team receives. Section scope, competitive agents, and patient cohorts are built around your asset and proposed label — not pulled from a generic NSCLC template.

AXLRx™ · Intelligence Brief · Competitive Intelligence

Non-Small Cell Lung Cancer — Pre-Launch Market Intelligence, US

Prepared for [Client] · Q2 2026 · 30 pages · Confidential

Contents

01The Strategic Casepp. 1–3
- Three decisions answered for your team, three confirmed open, and the commercial posture recommended before your first strategy review
- Pre-launch actions by function — commercial, medical affairs, market access — in order of urgency
- What secondary research can resolve now vs. what requires primary investigation
02The Binding Constraintpp. 4–7
- Which patients are IO-eligible — the molecular exclusion funnel that defines the real addressable pool
- PD-L1 testing penetration and the distribution gap between diagnosed NSCLC and biomarker-stratified patients
- The epidemiological assumptions your commercial team will be challenged on in the first strategy review
03The Patient Poolpp. 8–11
- Bottom-up build: incidence → systemic-eligible → IO-eligible by PD-L1 cohort and line of therapy
- Five-year projection with testing-rate and staging-mix sensitivity — where the model breaks
- The three assumptions that drive 80% of the variance in the addressable patient estimate
04The Competitive Mappp. 12–17
- Which agents hold which cohorts, on what clinical evidence, and what it would take to move prescribing share
- Trial-level analytical stack: OS · PFS · ORR across KEYNOTE, CheckMate, IMpower, PACIFIC, LAURA
- Pipeline entrants and pembrolizumab biosimilar entry — what the landscape looks like post-2028 LoE
05The Access Architecturepp. 18–21
- Coverage criteria by agent — what broad, restricted, and step-therapy gated look like for IO agents in practice
- The evidence standard payers will apply to your approval: not your trial design, theirs
- Gap analysis — where your clinical package strengthens the access case and where it does not
06The KOL Layerpp. 22–24
- The 20 investigators who publish, present, and set local practice patterns in IO NSCLC — by geography
- NCCN Thoracic panel positions and what the field currently believes about new mechanism entry
- Where prescribing influence concentrates and where new entrants have found early traction
07The Assumption Registerpp. 25–27
- Three patient capture scenarios — conservative, base, aggressive — built by cohort, not in aggregate
- The five inputs that drive variance: testing penetration, label scope, payer timeline, competitive response, switch rate
- Y1 · Y3 · Y5 patient volume and revenue by cohort — with the lever each decision-maker controls
08Client Alignment Questionspp. 28–30
- Evidence gaps secondary research cannot close — and the primary work your team would need to commission
- Payer conversations that must begin 12–18 months pre-approval to avoid formulary delay at launch
- Decisions contingent on label scope, trial outcomes, or competitive moves not yet visible
— Source Annex — all PMIDs, ClinicalTrials.gov IDs, and live URLs pp. A1–A6

At a glance

30pages across 8 structured sections

5commercial questions answered

72hfrom scope confirmation to delivery

100%of figures cited to live source

Readout call included

All deliveries include a 30-minute call with your analyst — to walk through findings and identify what your team needs to resolve next.

What You Receive

Three outputs delivered within 72 hours. Each built for a different role in your commercial team.

The intelligence analysis, the working model, and the board summary — delivered together. Your launch lead, your commercial analyst, and your leadership team each get what they need.

Core Deliverable

PDF

PDF · ~30 pages

Intelligence Brief

Structured for sequential reading by your launch lead, medical affairs director, and market access team. Every exhibit sourced. Every conclusion frames a decision.

Executive summary — 3 pages, decision-level
Disease landscape and patient funnel by cohort
Competitive landscape — agent map and trial data
Payer and reimbursement architecture
KOL landscape and documented positions
Strategic open questions and evidence gaps
Source annex — all PMIDs and live URLs

XLS

Excel Workbook

Patient Sizing Model

A live, editable model your commercial analyst can run sensitivities on without rebuilding. Assumptions are labelled and sourced throughout.

Bottom-up funnel — incidence to IO-eligible
Cohort splits by PD-L1 tier and therapy line
Three share scenarios with editable inputs
Revenue model with pricing and access timing
Sensitivity table — top 5 assumption levers

PPT

PowerPoint · Optional Add-on

Executive Deck

Five slides your leadership team can act on — for a pipeline review, investor briefing, or pre-launch alignment session. Structured around decisions, not descriptions.

Market opportunity — cohort-level, not aggregate
Competitive position and key threats
Payer readiness gap and what it requires
Patient capture scenarios Y1 · Y3 · Y5
Priority decisions and open questions

Sample Output

Exhibit 3 — Competitive landscape, NSCLC first line.

Your asset shown as [YOUR ASSET]. All competitor data drawn from live trial results and FDA prescribing information — cited by PMID at the exhibit foot. This is the depth and sourcing standard your team receives on every exhibit.

IO Agent Competitive Map — NSCLC First Line, US Market · Q2 2026 Sample · Illustrative

Agent (Sponsor)	PD-L1 Threshold	Approved 1L Setting	Pivotal Trial	mPFS	mOS	US Coverage	Share Est.
PembrolizumabKeytruda · Merck	≥50% (mono) / ≥1% (combo)	1L monotherapy (high PD-L1); 1L chemo combo all histologies	KEYNOTE-024, 189, 407	16.7 mo (mono)	26.3 mo (mono)	Broad	~52%
Nivolumab + IpilimumabOpdivo + Yervoy · BMS	Any (TMB signal)	1L IO-IO doublet all histologies	CheckMate-9LA, 227	6.7 mo	15.6 mo	Broad	~18%
AtezolizumabTecentriq · Roche/Genentech	Any (SP142 IHC)	1L combination regimens	IMpower110, IMpower150	7.1 mo	20.2 mo (high PD-L1)	Restricted	~8%
DurvalumabImfinzi · AstraZeneca	Stage III: any / 1L: any (LAURA)	Stage III post-CRT consolidation; emerging 1L	PACIFIC, LAURA (2024)	16.9 mo PFS2	47.5 mo (PACIFIC)	Broad (S-III) / Emerging (1L)	~12%
[YOUR ASSET][Client] · Confidential	TBD per proposed label	1L — scope confirmed at intake	Phase 3 ongoing	Pending	Pending	Pre-approval	See Exhibit 7

Sources: FDA prescribing information (pembrolizumab, nivolumab + ipilimumab, atezolizumab, durvalumab). KEYNOTE-024: Reck et al., NEJM 2016 · PMID 27718847. KEYNOTE-189: Gandhi et al., NEJM 2018 · PMID 29658856. KEYNOTE-407: Paz-Ares et al., NEJM 2018 · PMID 30280635. CheckMate-9LA: Reck et al., Lancet Oncol 2021 · PMID 34126067. CheckMate-227: Hellmann et al., NEJM 2018 · PMID 29658845. IMpower110: Spigel et al., NEJM 2021 · PMID 34280284. IMpower150: Socinski et al., NEJM 2018 · PMID 29863955. PACIFIC: Antonia et al., NEJM 2017 · PMID 28885881. LAURA: Lu et al., NEJM 2024. Prescribing share estimates derived from IQVIA MIDAS analogs; cited in full source annex.

Source Standard

Every figure is live-sourced before delivery. If a number cannot be verified, it does not appear.

The IO competitive landscape is a field where AI confidently reproduces outdated trial data, superseded payer policies, and retracted subgroup analyses. AXLRx uses none of its own memory as a source. Every figure your team receives is verified against a live document at the time of writing.

A wrong number in front of your payer or your leadership team is not recoverable in the same meeting.

Every claim cited to a live PMID, ClinicalTrials.gov ID, or URL at point of writing — uncited claims are dropped, not estimated
PubMed metadata fetched live during authoring — model memory produces incorrect author and journal data even on correct PMIDs
Numeric cross-check: the specific figure must appear in the cited source, not merely be consistent with its topic
Independent audit pass after generation — broken links, unsourced claims, and numeric inconsistencies flagged before delivery
Drop gate: any figure that cannot clear the above is removed. No confidence tiers. No exceptions.

Questions

What commercial teams ask before commissioning.

Scope

How is this different from a syndicated market research report?

A syndicated report describes the market. This frames the decisions your team needs to make. Every section answers a named commercial question your launch lead or market access director will face. It is decision-ready intelligence, not background reading.

Scope

Can scope be adjusted for our specific asset and proposed label?

Always. There is no generic NSCLC template. The competitive landscape is scoped to the agents your asset will face in your cohort. The payer analysis is built around your trial design, not a category average.

Delivery

How long does delivery take?

72 hours from scope confirmation. A 48-hour track is available for your board presentations or due diligence deadlines. All deliveries include a 30-minute readout call — your analyst walks your team through findings and identifies what to resolve next.

Sourcing

Are the figures verified or recalled from AI training data?

Every figure is cited to a live PMID or URL at the point of writing — never from model memory. A numeric cross-check confirms the figure appears in the cited source. If it cannot be verified, it does not appear.

Format

Do we receive editable files or fixed PDFs?

The PDF is fixed. Your Excel patient sizing model is fully editable — assumptions are labelled so your analyst can run sensitivities without rebuilding it. The PowerPoint deck is editable if commissioned as an add-on.

Process

What if we only need one section — payer analysis or the patient funnel?

Scoped standalone sections are available. Tell us at intake which questions your team needs answered. A scoped section typically delivers in 24–36 hours and is priced by scope, not the full rate.

Commission Your Analysis

Tell us your asset. Your team has the intelligence in 72 hours.

We build from your asset’s clinical profile — mechanism, biomarker strategy, proposed label, and target cohort. Scope confirmation takes one call.

Start Your Request

Or see a sample output to review the depth before committing.

Submit your asset profile

Drug, mechanism, proposed indication, target cohort, geography. Five minutes via the intake form.

Scope confirmed in 24 hours

We confirm scope with your team, clarify any ambiguities, and lock delivery timing. One call or email exchange.

Your analysis, delivered in 72 hours

PDF intelligence document, Excel model, and optional executive deck — with a 30-minute readout call included.

What your NSCLC commercial team needs to know before strategy is set.